(Q38093434)

28 August 2017

title

Practical issues, limitations, and periprocedural management of the NOAC's (English)

1 reference

28 August 2017

Gregory Connolly

1

1 reference

28 August 2017

Alex C Spyropoulos

series ordinal

2

1 reference

28 August 2017

publication date

1 August 2013

1 reference

Journal of Thrombosis and Thrombolysis

28 August 2017

published in

1 reference

28 August 2017

volume

36

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

212-222

1 reference

Epidemiology and management of bleeding in patients using vitamin K antagonists

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Rivaroxaban in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Apixaban with antiplatelet therapy after acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Apixaban in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Newer anticoagulants in 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

In vitro antioxidant and in vivo anti-inflammatory potential of crude polysaccharide from Turbinaria ornata (Marine Brown Alga).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Potential inaccuracy of point-of-care INR in dabigatran-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Oral rivaroxaban for symptomatic venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

How I treat anticoagulated patients undergoing an elective procedure or surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-0911-2

Dabigatran etexilate for prevention of venous thromboembolism

21 January 2018

1 reference

12 December 2020

Newly identified events in the RE-LY trial

1 reference

12 December 2020

Prevention and treatment of postoperative nausea and vomiting

1 reference

12 December 2020

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

1 reference

12 December 2020

Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial

1 reference

12 December 2020

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

1 reference

12 December 2020

10.1007/S11239-013-0911-2

Identifiers

DOI

1 reference

release_6xjqvoq4trhkhjxpyjyubtknq4

28 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6xjqvoq4trhkhjxpyjyubtknq4

24 November 2022

mapped directly with Wikidata item

1 reference